DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for craniofacial microsomia — screening already-approved drugs against its 12-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCraniofacial microsomia maps to a 12-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for craniofacial microsomia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endothelial PAS domain protein 1 (EPAS1) — EPAS1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet furan-2-ylmethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3H82 · 1.5 Å · ligand N-(furan-2-ylmethyl)-2-nitro-4-(trifluoromethyl)aniline (020). Experimental structure, not a prediction.
What the evidence adds up to
Craniofacial microsomia (CFM) is the second most common congenital facial condition treated in many craniofacial centres. It involves microtia, mandibular hypoplasia, and preauricular tags, and requires longitudinal multidisciplinary care. A European guideline published in 2020 provides an overview of optimal care provisions and recommendations for improvement, with a tailored version for patients and families. A phenotypic assessment tool offers a standardised method for classifying patients, intended for use in multicentre studies on cause, natural history, and comparative effectiveness. No drug treatment is mentioned in any of these abstracts.
Distraction osteogenesis was introduced decades ago and assumed instant popularity without evidence of advantage. One 2018 analysis states that poor long-term results and high rates of relapse prove this technique is unsuitable for all but the most carefully selected patients. The same author argues that many painful, useless operations would be avoided if surgeons better understood disease pathology and pathogenesis, and that new procedures must be rigorously tested against current protocols, independently of manufacturers. Three clinical cases described in another 2018 paper illustrate different therapies according to microsomia type, concluding that early, integrated treatment is needed and that patients must be monitored until growth is complete.
A 2022 survey study evaluated international diagnostic, screening, and monitoring practices for CFM and microtia, but its specific findings are not reported in the available abstracts. No randomised controlled trials, survival data, or response rates appear in any of these abstracts. The literature remains focused on classification, surgical technique, and care coordination.
What is still missing: any drug therapy or biological intervention for CFM; randomised trials comparing surgical approaches; prospective data on long-term functional outcomes; and funding for multicentre natural history studies that could identify patient subgroups most likely to benefit from specific interventions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part C Seminars in Medical Genetics · 2013 · 60 citations
Clinical care in craniofacial microsomia: A review of current management recommendations and opportunities to advance research
AbstractCraniofacial microsomia (CFM) is a complex condition associated with microtia, mandibular hypoplasia, and preauricular tags. It is the second most common congenital facial condition treated in many craniofacial centers and requires longitudinal multidisciplinary patient care. The purpose of this article is to summarize current recommendations for clinical management and discuss opportunities to advance clinical research in CFM.
Journal of Craniofacial Surgery · 2021 · 6 citations · open access
European Guideline on Craniofacial Microsomia: A Version for Patients and Families
AbstractABSTRACT: A European guideline on craniofacial microsomia was developed within the European Reference Network for rare and/or complex craniofacial anomalies and ear, nose, and throat disorders and published in 2020. The guideline provides an overview of optimal care provisions for patients with craniofacial microsomia and recommendations for the improvement of care. This document seeks to provide a tailored overview of this guideline for patients and their families.
Journal of Craniofacial Surgery · 2018 · 4 citations
Craniofacial Microsomia: Orthodontic Surgical Treatment of Growing Patients
AbstractCraniofacial microsomia covers a set of morphogenetic anomalies that affect structures arising from the first and second brachial arches. Due to the vast phenotypic variation and complexity of the malformation, a global treatment that is coordinated by a multidisciplinary team is imperative. Herein, the authors describe 3 clinical patients and discuss the different therapies used according to the type of microsomia present. It was concluded that early and integrated treatment, which considers all the affected and potentially affected soft and hard tissue, is needed, and that patients must be monitored until they have finished growing.
Australasian Journal of Plastic Surgery · 2018 · 2 citations · open access
A critical analysis of the management of craniofacial microsomia
AbstractDistraction osteogenesis was introduced into the management of craniofacial microsomia some decades ago. It assumed almost instant popularity without evidence of advantage. Poor long-term results and high rates of relapse prove this technique is unsuitable for all but the most carefully selected patients. While innovation and technological advances are to be celebrated, it is vital that new procedures are rigorously tested against current protocols. It is also imperative, that thorough knowledge of disease pathology and pathogenesis are applied against new procedures. It is the view of the author that many painful, useless operations would be avoided if surgeons better understood these key fundamentals. Furthermore, there must be clear guidelines for the introduction of new techniques and devices, and this must happen independently of manufacturers.
Optimal Classifier Selection for Adaptive Boosting Algorithm.
AbstractThe phenotypic assessment tool for craniofacial microsomia protocol provides a simple and standardized method for practitioners and researchers to classify patients with craniofacial microsomia. We anticipate that this tool can be used in multicenter investigational studies to evaluate the cause of this condition, its natural history, and comparative effectiveness research.
Sage Journals Data · 2022 · 0 citations · open access
sj-docx-3-cpc-10.1177_10556656221093912 - Supplemental material for Evaluating International Diagnostic, Screening, and Monitoring Practices for Craniofacial Microsomia and Microtia: A Survey Study
AbstractSupplemental material, sj-docx-3-cpc-10.1177_10556656221093912 for Evaluating International Diagnostic, Screening, and Monitoring Practices for Craniofacial Microsomia and Microtia: A Survey Study by Elsa M. Ronde, Jitske W. Nolte, Frea H. Kruisinga, Saskia M. Maas, Oren Lapid, Fenna A. Ebbens, Alfred G. Becking and Corstiaan C. Breugem in The Cleft Palate-Craniofacial Journal
Sage Journals Data · 2022 · 0 citations · open access
sj-jpg-5-cpc-10.1177_10556656221093912 - Supplemental material for Evaluating International Diagnostic, Screening, and Monitoring Practices for Craniofacial Microsomia and Microtia: A Survey Study
AbstractSupplemental material, sj-jpg-5-cpc-10.1177_10556656221093912 for Evaluating International Diagnostic, Screening, and Monitoring Practices for Craniofacial Microsomia and Microtia: A Survey Study by Elsa M. Ronde, Jitske W. Nolte, Frea H. Kruisinga, Saskia M. Maas, Oren Lapid, Fenna A. Ebbens, Alfred G. Becking and Corstiaan C. Breugem in The Cleft Palate-Craniofacial Journal
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
